CompletedNCT03490786
A Dose Escalating Study to Assess the Safety and Tolerability of GT-001
Medication studyAges 18+United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- TustinSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: July 16, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Gila Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT03490786
- Official title
Show the full official title
A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.
Recruitment & locations
CompletedTustin
Questions about this study
Who is behind this study?
The study sponsor is Gila Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including GT-001.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me